Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 96,950 Shares

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) COO Eric Venker sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $10.81 on Friday. The firm has a fifty day simple moving average of $10.64 and a 200-day simple moving average of $10.49. The company has a debt-to-equity ratio of 0.29, a quick ratio of 5.84 and a current ratio of 5.84. Roivant Sciences Ltd. has a twelve month low of $6.59 and a twelve month high of $13.24.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last announced its earnings results on Monday, November 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The business had revenue of $37.10 million during the quarter, compared to the consensus estimate of $26.68 million. Roivant Sciences had a negative net margin of 951.77% and a negative return on equity of 73.04%. Equities analysts expect that Roivant Sciences Ltd. will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB boosted its stake in Roivant Sciences by 396.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 67,000 shares of the company’s stock valued at $675,000 after acquiring an additional 53,500 shares during the last quarter. Artia Global Partners LP boosted its stake in Roivant Sciences by 422.5% during the 2nd quarter. Artia Global Partners LP now owns 824,363 shares of the company’s stock valued at $8,310,000 after acquiring an additional 666,600 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Roivant Sciences during the 3rd quarter valued at $4,200,000. Ausdal Financial Partners Inc. bought a new position in Roivant Sciences during the 2nd quarter valued at $101,000. Finally, Bank of New York Mellon Corp boosted its stake in Roivant Sciences by 68.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,187,928 shares of the company’s stock valued at $13,875,000 after acquiring an additional 480,946 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on ROIV. Guggenheim decreased their price objective on shares of Roivant Sciences from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Deutsche Bank Aktiengesellschaft began coverage on shares of Roivant Sciences in a research note on Tuesday, December 12th. They set a “buy” rating and a $14.00 price objective for the company. Bank of America boosted their price objective on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 2nd. JPMorgan Chase & Co. decreased their price objective on shares of Roivant Sciences from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Tuesday, November 14th. Finally, Piper Sandler began coverage on shares of Roivant Sciences in a research note on Friday, January 5th. They set an “overweight” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.56.

Get Our Latest Report on ROIV

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

See Also

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.